2022
DOI: 10.1016/j.jaci.2021.12.578
|View full text |Cite
|
Sign up to set email alerts
|

Patients with Pseudoallergic Reactions Following COVID-19 Vaccination are Able to Tolerate Subsequent Dosing

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
1
1

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…9,10,16,19 These allergy-like reactions arise without prior sensitization, by way of direct and/or indirect stimulation of mast cells and also, macrophages, platelets, granulocytes, which are typically not involved in Type-1 allergy. [20][21][22][23] The latter cells can be activated both by direct binding of reactive NPs to their inflammatory signal receptors, and/or anaphylatoxins (C3a, C5a) to their specific surface receptors (C3aR, C5aR). Because anaphylatoxins are byproducts of complement (C) activation, the reactions proceeding through the latter pathway are referred to as C activation-related pseudoallergy (CARPA) 24 although C activation may be only a co-trigger.…”
Section: Introductionmentioning
confidence: 99%
“…9,10,16,19 These allergy-like reactions arise without prior sensitization, by way of direct and/or indirect stimulation of mast cells and also, macrophages, platelets, granulocytes, which are typically not involved in Type-1 allergy. [20][21][22][23] The latter cells can be activated both by direct binding of reactive NPs to their inflammatory signal receptors, and/or anaphylatoxins (C3a, C5a) to their specific surface receptors (C3aR, C5aR). Because anaphylatoxins are byproducts of complement (C) activation, the reactions proceeding through the latter pathway are referred to as C activation-related pseudoallergy (CARPA) 24 although C activation may be only a co-trigger.…”
Section: Introductionmentioning
confidence: 99%